Clerkenwell Health to Open Psychedelics Research Facility in London

A UK research startup, Clerkenwell Health, is launching Europe’s first commercial research facility for clinical trials of psychedelic drugs.

Founded in January 2021, the company has been working to develop clinical trials with drugmakers, including Denmark-based Octarine Bio and the Canada-headquartered Psyence Group.

The London facility, which will open in August, will initially focus on the use of psilocybin as a treatment for anxiety in terminally ill patients.

Researchers and regulators are meeting today to discuss the future of psychedelics research at the Agenda for Psych Symposium in London.

In the U.S., the FDA has already granted Breakthrough Therapy status for two psychedelics, psilobicin and MDMA (3,4-methylenedioxymethamphetamine).